Header Logo

Connection

WEN-JEN HWU to Melanoma

Back to Details
This is a "connection" page, showing publications WEN-JEN HWU has written about Melanoma.
WEN-JEN HWU
Connection Strength
6.228
Melanoma
  1. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021 02; 144:182-191.
    View in: PubMed
    Score: 0.230
  2. Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Arch Med Res. 2020 11; 51(8):827-838.
    View in: PubMed
    Score: 0.226
  3. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer. 2018 Dec 19; 18(1):1274.
    View in: PubMed
    Score: 0.200
  4. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update. Discov Med. 2018 01; 25(135):31-40.
    View in: PubMed
    Score: 0.187
  5. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340.
    View in: PubMed
    Score: 0.185
  6. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017 Aug; 16(8):933-940.
    View in: PubMed
    Score: 0.181
  7. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017 02; 27(1):24-31.
    View in: PubMed
    Score: 0.176
  8. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discov Med. 2015 May; 19(106):393-401.
    View in: PubMed
    Score: 0.156
  9. Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov; 14(11):1709-18.
    View in: PubMed
    Score: 0.149
  10. A phase I study of decitabine with pegylated interferon a-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. 2014 Oct; 32(5):969-75.
    View in: PubMed
    Score: 0.146
  11. Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther. 2012 Jun; 12(6):773-82.
    View in: PubMed
    Score: 0.126
  12. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8.
    View in: PubMed
    Score: 0.126
  13. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011 Dec; 197(6):W992-W1000.
    View in: PubMed
    Score: 0.123
  14. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. 2010 Dec; 20(6):501-6.
    View in: PubMed
    Score: 0.115
  15. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 01; 106(11):2445-51.
    View in: PubMed
    Score: 0.084
  16. Hypertrophic osteoarthropathy associated with metastatic melanoma. Melanoma Res. 2005 Dec; 15(6):559-61.
    View in: PubMed
    Score: 0.081
  17. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005 Jun 15; 103(12):2590-7.
    View in: PubMed
    Score: 0.078
  18. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005 Jun; 6(6):438-9.
    View in: PubMed
    Score: 0.078
  19. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003 Nov 01; 9(14):5214-20.
    View in: PubMed
    Score: 0.070
  20. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3351-6.
    View in: PubMed
    Score: 0.069
  21. Diagnosis and management of stage I/II melanoma. Semin Oncol Nurs. 2003 Feb; 19(1):22-31.
    View in: PubMed
    Score: 0.067
  22. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res. 2002 Aug; 12(4):381-7.
    View in: PubMed
    Score: 0.064
  23. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002 Jun 01; 20(11):2610-5.
    View in: PubMed
    Score: 0.064
  24. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001 Oct; 2(10):634-5.
    View in: PubMed
    Score: 0.061
  25. Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. Arch Pathol Lab Med. 2021 08 01; 145(8):943-952.
    View in: PubMed
    Score: 0.060
  26. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2021 07 01; 145(7):842-850.
    View in: PubMed
    Score: 0.060
  27. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol. 2021 03; 34(3):572-583.
    View in: PubMed
    Score: 0.056
  28. Staging work-up and post-treatment surveillance of patients with melanoma. Clin Plast Surg. 2000 Jul; 27(3):377-90, viii.
    View in: PubMed
    Score: 0.056
  29. Systemic chemotherapy. Clin Plast Surg. 2000 Jul; 27(3):451-61, ix-x.
    View in: PubMed
    Score: 0.056
  30. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 10 01; 26(19):5086-5091.
    View in: PubMed
    Score: 0.056
  31. TERT amplification but not activation of canonical Wnt/?-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Mod Pathol. 2020 10; 33(10):2067-2074.
    View in: PubMed
    Score: 0.055
  32. BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. Am J Dermatopathol. 2020 May; 42(5):313-321.
    View in: PubMed
    Score: 0.055
  33. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
    View in: PubMed
    Score: 0.055
  34. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202.
    View in: PubMed
    Score: 0.052
  35. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019 04 01; 30(4):582-588.
    View in: PubMed
    Score: 0.051
  36. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma. JAMA Ophthalmol. 2018 11 01; 136(11):1236-1241.
    View in: PubMed
    Score: 0.050
  37. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.050
  38. Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiol. 2018 12; 57:80-84.
    View in: PubMed
    Score: 0.049
  39. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.049
  40. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.048
  41. Desmoplastic Melanoma of the Periorbital Region. Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr; 34(2):e48-e52.
    View in: PubMed
    Score: 0.047
  42. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815.
    View in: PubMed
    Score: 0.047
  43. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.047
  44. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350.
    View in: PubMed
    Score: 0.047
  45. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674.
    View in: PubMed
    Score: 0.047
  46. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.046
  47. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
    View in: PubMed
    Score: 0.046
  48. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210.
    View in: PubMed
    Score: 0.045
  49. Aberrant expression of FLI-1 in melanoma. J Cutan Pathol. 2017 Sep; 44(9):790-793.
    View in: PubMed
    Score: 0.045
  50. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg. 2017 Jul/Aug; 33(4):e82-e85.
    View in: PubMed
    Score: 0.045
  51. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immunother. 2017 Oct; 66(10):1359-1366.
    View in: PubMed
    Score: 0.045
  52. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105.
    View in: PubMed
    Score: 0.044
  53. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016 12; 26(6):604-608.
    View in: PubMed
    Score: 0.043
  54. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109.
    View in: PubMed
    Score: 0.043
  55. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.042
  56. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9.
    View in: PubMed
    Score: 0.042
  57. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7.
    View in: PubMed
    Score: 0.041
  58. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97.
    View in: PubMed
    Score: 0.040
  59. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res. 2015 Nov; 3(11):1201-6.
    View in: PubMed
    Score: 0.040
  60. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.039
  61. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers. 1994 Oct-Dec; 9(4):247-50.
    View in: PubMed
    Score: 0.037
  62. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol. 1994 Oct; 17(5):430-1.
    View in: PubMed
    Score: 0.037
  63. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.037
  64. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8.
    View in: PubMed
    Score: 0.037
  65. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17.
    View in: PubMed
    Score: 0.037
  66. Case of vemurafenib-induced Sweet's syndrome. J Dermatol. 2014 Sep; 41(9):817-20.
    View in: PubMed
    Score: 0.036
  67. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44.
    View in: PubMed
    Score: 0.034
  68. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
    View in: PubMed
    Score: 0.034
  69. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
    View in: PubMed
    Score: 0.033
  70. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
    View in: PubMed
    Score: 0.033
  71. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012 Aug; 22(4):310-5.
    View in: PubMed
    Score: 0.032
  72. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5.
    View in: PubMed
    Score: 0.032
  73. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99.
    View in: PubMed
    Score: 0.032
  74. Chemoprevention for brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):63-9.
    View in: PubMed
    Score: 0.031
  75. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.031
  76. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol. 2011 Dec; 34(6):603-10.
    View in: PubMed
    Score: 0.031
  77. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011 Aug; 21(4):357-63.
    View in: PubMed
    Score: 0.030
  78. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.030
  79. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul; 47(10):1476-83.
    View in: PubMed
    Score: 0.030
  80. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res. 2011 Apr; 21(2):127-30.
    View in: PubMed
    Score: 0.029
  81. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. 2011 Feb; 21(1):84-90.
    View in: PubMed
    Score: 0.029
  82. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol. 2011 Mar; 66(3):224-36.
    View in: PubMed
    Score: 0.029
  83. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010 Dec; 20(6):507-10.
    View in: PubMed
    Score: 0.029
  84. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2011 Aug; 51(8):1205-12.
    View in: PubMed
    Score: 0.028
  85. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011 Apr 15; 117(8):1687-96.
    View in: PubMed
    Score: 0.028
  86. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77.
    View in: PubMed
    Score: 0.028
  87. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar; 67(3):657-66.
    View in: PubMed
    Score: 0.028
  88. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol. 2009 Oct; 32(5):509-14.
    View in: PubMed
    Score: 0.026
  89. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009 Aug; 27(7):756-63.
    View in: PubMed
    Score: 0.026
  90. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009 Aug; 19(4):238-42.
    View in: PubMed
    Score: 0.026
  91. The predictive value of lymphoscintigraphy for nodal metastases of cutaneous melanoma. Conn Med. 1999 Jul; 63(7):387-90.
    View in: PubMed
    Score: 0.026
  92. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.025
  93. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2009 Jun; 64(1):161-7.
    View in: PubMed
    Score: 0.025
  94. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008 Jul; 26(6):624-33.
    View in: PubMed
    Score: 0.024
  95. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008 Apr; 5(2):201-7.
    View in: PubMed
    Score: 0.024
  96. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery. 1998 Mar; 123(3):335-43.
    View in: PubMed
    Score: 0.024
  97. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008 Apr; 10(2):199-207.
    View in: PubMed
    Score: 0.024
  98. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20; 25(15):2078-85.
    View in: PubMed
    Score: 0.022
  99. Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg. 1997 Apr; 99(4):1023-9.
    View in: PubMed
    Score: 0.022
  100. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res. 1997 Apr; 7(2):147-51.
    View in: PubMed
    Score: 0.022
  101. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006 Dec; 244(6):1012-7.
    View in: PubMed
    Score: 0.022
  102. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006 Oct 15; 107(8):1883-90.
    View in: PubMed
    Score: 0.022
  103. Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg. 1996 Sep; 37(3):286-92.
    View in: PubMed
    Score: 0.021
  104. Multiple primary melanomas: data and significance. Plast Reconstr Surg. 1995 Nov; 96(6):1384-9.
    View in: PubMed
    Score: 0.020
  105. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine. 2004 Jul 29; 22(21-22):2904-9.
    View in: PubMed
    Score: 0.018
  106. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res. 2004 Jul 15; 10(14):4717-23.
    View in: PubMed
    Score: 0.018
  107. Eruptive melanotic macules and papules associated with adenocarcinoma. J Cutan Pathol. 2003 Aug; 30(7):463-9.
    View in: PubMed
    Score: 0.017
  108. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993 Apr; 11(4):638-43.
    View in: PubMed
    Score: 0.017
  109. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res. 2003 Apr; 13(2):189-96.
    View in: PubMed
    Score: 0.017
  110. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002 May; 8(5):967-72.
    View in: PubMed
    Score: 0.016
  111. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.015
  112. Colonic melanoma, primary or regressed primary. J Clin Gastroenterol. 2000 Jun; 30(4):441-4.
    View in: PubMed
    Score: 0.014
  113. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018 Jul; 45(7):504-507.
    View in: PubMed
    Score: 0.012
  114. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.011
  115. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183.
    View in: PubMed
    Score: 0.008
  116. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28; 366(26):2455-65.
    View in: PubMed
    Score: 0.008
  117. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer. 2012 Oct; 20(10):2583-8.
    View in: PubMed
    Score: 0.008
  118. Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res. 2003 Dec; 13(6):595-601.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.